How does Pau D'Arco work as an antifungal and antimicrobial?

Pau D'Arco works primarily through active compounds called lapachol and beta-lapachone. These naphthoquinones disrupt the electron transport chain in microbial cells, effectively interfering with their ability to generate energy. This mechanism inhibits the growth of various fungi, bacteria, and viruses. While laboratory studies (Evidence Level C) demonstrate these antimicrobial properties, clinical trials confirming the specific mechanism of action in humans are currently limited.

Does Pau D'Arco interact with blood thinners like Warfarin?

Yes, Pau D'Arco has significant anticoagulant properties and can interact with blood-thinning medications. The compound lapachol inhibits blood clotting, which may potentiate the effects of anticoagulant drugs like warfarin or antiplatelet medications like aspirin. This combination increases the risk of bleeding and bruising. Patients taking anticoagulants should avoid Pau D'Arco unless specifically monitored by a healthcare provider (Evidence Level C/D).

What is the recommended dosage for Pau D'Arco inner bark?

Traditional adult dosage involves preparing a decoction using 15-20 grams of dried inner bark, simmered in water for 10-15 minutes, consumed up to three times daily. For standardized extracts, a common dosage is 300 mg taken three times daily. It is crucial to use the inner bark specifically, as other parts of the tree contain lower concentrations of active compounds. Dosage recommendations are based on traditional use and pharmacological data (Evidence Level C).

Is Pau D'Arco safe to take during pregnancy?

No, Pau D'Arco is considered unsafe during pregnancy and breastfeeding. The active compound lapachol has demonstrated potential toxic effects and uterine stimulant activity in animal studies, which could lead to miscarriage or fetal harm. Historical texts and modern herbalists contraindicate its use for expectant mothers. Women who are pregnant or nursing should avoid Pau D'Arco supplements and teas entirely (Evidence Level D/Traditional).

Can Pau D'Arco be used to treat Candida overgrowth?

Pau D'Arco is traditionally used to treat Candida yeast infections due to its antifungal properties. In vitro studies show that beta-lapachone inhibits the growth of Candida species by disrupting cell wall formation. While these results are promising, high-quality human clinical trials are lacking (Evidence Level C). It is often used as a complementary tea or extract, but should not replace standard antifungal medications without professional guidance.

Pau Darco Inner (Tabebuia impetiginosa)

PubMed-compiled information sheet

This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.

Compiled from 30 PubMed articles · model: gemma4:31b

Summary

Pau Darco (Tabebuia impetiginosa), also known as Taheebo, is a South American canopy tree whose inner bark is used in traditional medicine for various infections and inflammatory conditions [PMID:18992801, PMID:32962180].

Background

Tabebuia impetiginosa is a plant native to the Amazon rainforest and other regions of Latin America [PMID:32962180]. It is often referred to as Red Lapacho or Taheebo [PMID:18992801, PMID:28927490].

Traditional uses

Traditionally, a decoction of the inner bark is used to treat bacterial and fungal infections, fever, syphilis, malaria, trypanosomiasis, stomach and bladder disorders, and skin diseases [PMID:18992801, PMID:32962180]. It has also been used as a general tonic, immunostimulant, adaptogen, and for motor disorders [PMID:35240121], as well as for memory enhancement and central nervous system stimulation [PMID:38705428].

Active compounds

Identified compounds include naphthoquinones such as lapachol, $\beta$-lapachone, and $\alpha$-lapachone [PMID:28586252, PMID:21637695]. Other constituents include 2-(hydroxymethyl)anthraquinone, anthraquinone-2-carboxylic acid [PMID:16359837], veratric acid [PMID:28927490], cyclopentene dialdehydes [PMID:10820794], and various iridoid, phenylethanoid, phenolic, and lignan glycosides [PMID:15721952, PMID:15280007, PMID:16394542]. Volatile constituents include 4-methoxybenzaldehyde, 4-methoxyphenol, elemicin, trans-anethole, and 4-methoxybenzyl alcohol [PMID:12502424].

Mechanism of action

The herb may suppress the production of prostaglandin E(2) and nitric oxide (NO) by blocking the mRNA expression of COX-II and iNOS through the interruption of ERK activation [PMID:18634864]. Lapachol and $\beta$-lapachone may induce apoptosis by generating oxygen-reactive species and inhibiting topoisomerases I and II [PMID:21637695]. Inner bark extracts have also been shown to inhibit platelet aggregation and vascular smooth muscle cell proliferation by suppressing arachidonic acid liberation and ERK1/2 MAPK activation [PMID:16766151].

Clinical evidence

Evidence BPrimary Dysmenorrhea

A single-arm, open-label trial of 1050 mg/day of encapsulated Tabebuia avellanedae in 12 women found the treatment to be safe and tolerable [PMID:36960315].

Evidence DHelicobacter pylori

In vitro assays showed that 2-(hydroxymethyl)anthraquinone exhibited strong growth-inhibiting activity against H. pylori [PMID:16359837].

Evidence DCancer (Cell Lines)

Extracts showed cytotoxicity in human tumor cell lines (MCF-7, NCI-H460, HeLa, and HepG2) [PMID:26703544] and dose-dependent growth inhibition and apoptosis in ER+ MCF-7 breast cancer cells [PMID:19578798].

Evidence DInflammation/Pain

Animal models demonstrated significant anti-nociceptive and anti-inflammatory effects at 200 mg/kg [PMID:22888300, PMID:22825254].

Evidence DPostprandial Triglycerides

Bark extract significantly delayed the postprandial increase of plasma triglycerides in rats by inhibiting pancreatic lipase [PMID:22431070].

Evidence D

Safety & adverse effects

A clinical trial for dysmenorrhea reported the herb was safe and tolerable [PMID:36960315]. However, a study on Wistar rats found that flower extract (not bark) caused a significant increase in DNA damage in blood and liver cells at doses of 300 and 500 mg/kg [PMID:22888300].

Evidence summary

The evidence consists primarily of in vitro studies and animal models (Level D), with one small, open-label clinical trial (Level B) focusing on safety and tolerability. There is a lack of large-scale RCTs or systematic reviews to confirm clinical efficacy in humans.

PubMed sources

1.PMID: 18992801 (2009) — Red Lapacho (Tabebuia impetiginosa)--a global ethnopharmacological commodity? · Journal of ethnopharmacology
2.PMID: 32962180 (2020) — Tabebuia impetiginosa: A Comprehensive Review on Traditional Uses, Phytochemistry, and Immunopharmacological Properties. · Molecules (Basel, Switzerland)
3.PMID: 10820794 (2000) — Cyclopentene dialdehydes from Tabebuia impetiginosa. · Phytochemistry
4.PMID: 35240121 (2022) — Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates. · Annales pharmaceutiques francaises
5.PMID: 34361435 (2021) — Evaluation of the Mechanical and Biocidal Properties of Lapacho from Tabebuia Plant as a Biocomposite Material.

Pau Darco Inner

Sources & Citations

Kunzea Ambigua

Prunus avium

Oroxylum Indicum

Summary

Background

Traditional uses

Active compounds

Mechanism of action

Clinical evidence

Safety & adverse effects

Evidence summary

PubMed sources

Government sources

Pau Darco Inner

Sources & Citations

Related Herbs

Kunzea Ambigua

Prunus avium

Oroxylum Indicum

Summary

Background

Traditional uses

Active compounds

Mechanism of action

Clinical evidence

Safety & adverse effects

Evidence summary

PubMed sources

Government sources